NASDAQ : AGIO
Agios Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 30.55 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.82B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.87B |
| Enterprise Value | 939.19M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 59.70M |
| Shares Outstanding | 59.70M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 100.12% |
| Float | 50.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.07 |
| Forward PS | 7.12 |
| PB Ratio | 1.74 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 9.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.22 |
| Quick Ratio | 9.14 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -34.34% |
| Return on Assets (ROA) | -22.24% |
| Return on Invested Capital (ROIC) | -108.33% |
| Return on Capital Employed (ROCE) | -44.21% |
| Weighted Average Cost of Capital (WACC) | 7.53% |
| Revenue Per Employee | $182,107 |
| Profits Per Employee | -$761,641 |
| Employee Count | 540 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 11.95 |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.02M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -27.29% |
| 50-Day Moving Average | 33.54 |
| 200-Day Moving Average | 31.73 |
| Relative Strength Index (RSI) | 41.79 |
| Average Volume (20 Days) | 1,286,379 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.89M |
| Short Previous Month | 7.02M |
| Short % of Shares Out | 11.55% |
| Short % of Float | 13.79% |
| Short Ratio (days to cover) | 5.82 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 98.34M |
| Gross Profit | -266.29M |
| Operating Income | -459.02M |
| Pretax Income | -412.30M |
| Net Income | -411.29M |
| EBITDA | -453.67M |
| EBIT | -459.02M |
| Loss Per Share | -$7.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 617.58M |
| Total Debt | 31.17M |
| Net Cash | 933.66M |
| Net Cash Per Share | $15.64 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 17.21 |
| Working Capital | 647.45M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -360.60M |
| Capital Expenditures | -4.66M |
| Depreciation & Amortization | 5.35M |
| Net Borrowing | n/a |
| Free Cash Flow | -365.25M |
| FCF Per Share | -$6.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | -270.79% |
| Operating Margin | -466.78% |
| Pretax Margin | -419.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | -22.34% |
| FCF Yield | -19.48% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $45.88 |
| Price Target Difference | 46.25% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 112.11% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.47 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |